Phoenix Financial Publishes Financial Statements for Q3 and the First Nine Months of 2024

In This Article:

Continued growth and higher core income in the first 9 months and Q3

Comprehensive income for first nine months totaled NIS 1.3 billion, with return on equity at 16.1%, and accelerated growth of 28% in Asset Management, Credit, and Distribution (Agencies) in the first 9 months, compared to 2023

TEL AVIV, Israel, Nov. 27, 2024 /PRNewswire/ -- Phoenix Financial Ltd. (formerly Phoenix Holdings), a leading Israel-based financial, insurance, and investment group (TLV:PHOE) ("Phoenix," the "Group," or the "Company"), today reported its results for the three and nine months ended September 30, 2024.

Comprehensive income and return on equity

In the third quarter of 2024, Phoenix reports NIS 617 million in comprehensive income, resulting in NIS 2.46 in earnings per share and a 24.4% in return on equity. Core comprehensive income for the quarter (without non-operating effects such as capital market impact above or below 3% real returns, interest rate effects, and Special Items) totaled NIS 474 million, reflecting an 18.6% core ROE.

Comprehensive income for the first nine months of 2024 totaled NIS 1,284 million, resulting in NIS 5.11 in earnings per share and a 16.1% in return on equity. Core comprehensive income for the first nine months totaled NIS 1,342 million reflecting a 16.8% core ROE.

Continued growth in profitability and activities

Asset Management, Distribution (Agencies), and Credit: Comprehensive income in the third quarter of 2024 and the first nine months of 2024 totaled NIS 159 million and NIS 433 million, respectively, compared to NIS 123 million and NIS 338 million in 2023, reflecting an increase of 28% for the first nine months of the year; adjusted EBITDA totaled NIS 290 million and NIS 854 million in the third quarter and first nine months 2024, respectively, on a consolidated basis, including minority interests;

Insurance: Core comprehensive income from Insurance totaled NIS 315 million and NIS 909 million in the third quarter and first nine months of 2024, respectively, compared to NIS 182 million and NIS 617 in the in the corresponding periods in the prior year, mostly due to an improvement in the P&C and Health segments;

Non-operating effects: non-operating income had a positive contribution of NIS 143 million in the third quarter of 2024, primarily due to capital market performance above a real 3% return in addition to the effect of actuarial studies, partially offset by the interest rate effects; capital market returns reduced the gap in receivable variable management fees to NIS 165 million as of September 30, 2024 and to NIS 58 million as of the publication date of the financial statements;